Zhong, W.; Shen, Z.; Wang, M.; Wang, H.; Sun, Y.; Tao, X.; Hou, D.
Tumor Microenvironment Responsive Nanomicelle with Folic Acid Modification Co-Delivery of Doxorubicin/Shikonin for Triple Negative Breast Cancer Treatment. Pharmaceuticals 2023, 16, 374.
https://doi.org/10.3390/ph16030374
AMA Style
Zhong W, Shen Z, Wang M, Wang H, Sun Y, Tao X, Hou D.
Tumor Microenvironment Responsive Nanomicelle with Folic Acid Modification Co-Delivery of Doxorubicin/Shikonin for Triple Negative Breast Cancer Treatment. Pharmaceuticals. 2023; 16(3):374.
https://doi.org/10.3390/ph16030374
Chicago/Turabian Style
Zhong, Wu, Zhehao Shen, Menglan Wang, Hongyi Wang, Yuting Sun, Xiaojun Tao, and Defu Hou.
2023. "Tumor Microenvironment Responsive Nanomicelle with Folic Acid Modification Co-Delivery of Doxorubicin/Shikonin for Triple Negative Breast Cancer Treatment" Pharmaceuticals 16, no. 3: 374.
https://doi.org/10.3390/ph16030374
APA Style
Zhong, W., Shen, Z., Wang, M., Wang, H., Sun, Y., Tao, X., & Hou, D.
(2023). Tumor Microenvironment Responsive Nanomicelle with Folic Acid Modification Co-Delivery of Doxorubicin/Shikonin for Triple Negative Breast Cancer Treatment. Pharmaceuticals, 16(3), 374.
https://doi.org/10.3390/ph16030374